Basel Area has ever more to offer investors
The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than 500 million Swiss francs were invested in startups in this canton.
Basel is an ideal place for business
Investment in Swiss startups totaled 2.1 billion francs in 2020, the latest Swiss Venture Capital Report has found. The Report is compiled by the news portal startupticker.ch in collaboration with the Swiss Private Equity & Corporate Finance Association (SECA). While this is a decline of 7.4 percent on the previous year, a press release highlights that for the first time since 2017, more money was invested in biotech than in ICT startups. As a result, Basel-Stadt was the big winner of the cantons.
Overall, startups in the canton received 540.4 million francs, which is more than a quarter of the total money invested and exceeds the previous record in 2018 fourfold. Since the first Swiss Venture Capital Report 2012, investment in startups from Basel-Stadt has increased by 403 percent. Of the 540.4 million francs, 530 million francs went to biotech companies, the biggest investment throughout Switzerland.
One company that contributed greatly was Versant Ventures. The international healthcare venture capital firm has just one of its biotech incubators in Europe – at the Technologiepark Basel. According to Alex Mayweg, Managing Director of Versant Ventures, the Basel Area border triangle is developing very rapidly from a classic pharma to a first-class biotech location at the moment.
Basel-Stadt also saw an increase in funds raised through financing rounds last year. With 29 rounds, Basel-Stadt has climbed the cantonal rankings from fifth place in 2019 to third in 2020. When it comes to total investment, Basel-Stadt has put an end to the dominance of the two sites of the Swiss Federal Institutes of Technology in Zurich and Vaud to take a clear second place behind Zurich.
Share this article
You may also be interested in
Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...Read More